A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor ...
A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor ...
Co announces that it has licensed from Bristol-Myers Squibb (BMY) a selective androgen receptor modulator program, including a lead compound in Phase 1 clinical development and back-up compounds.
Impact of BMI on CDK4/6 inhibitors efficacy and safety in advanced breast cancer: Results from a propensity score matched study—CAMELIA. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today a scientific presentation will be made at the 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013, in San Antonio, ...
Testing the cutaneous absorption of lorazepam, diphenhydramine, and haloperidol gel (ABH gel) used for cancer-related nausea. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This ...
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and ...
-- Topline clinical data expected in the fourth quarter calendar year 2024 -- “While there is clear medical benefit from weight loss with semaglutide, improving weight loss quality by minimizing the ...
Co announces data from a preclinical study on its Selective Androgen Receptor Modulator LGD-3303 at the American Society for Bone and Mineral Research Annual Meeting in Honolulu, Hawaii on Sept 16, ...
LONDON--(BUSINESS WIRE)--Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, will present a “Trial in Progress” ...
This new study, therefore, tested a completely different approach. The orally administered drug enobosarm is a selective androgen receptor modulator, which can stimulate androgen receptor activity in ...
MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results